Does Dapsone Cause Hepatotoxicity?
Yes, dapsone can cause hepatotoxicity, though it is uncommon and typically reversible when the drug is discontinued. The hepatotoxic effects range from mild, reversible increases in liver transaminases to rare but potentially fatal acute hepatic necrosis as part of dapsone hypersensitivity syndrome.
Hepatotoxicity Profile
Documented Hepatic Effects
Reversible transaminase elevations occur in a small percentage of patients receiving dapsone 1. The 1991 CDC guidelines specifically note that "nausea, vomiting, and reversible increases in liver transaminases have been noted among a small percentage of patients" treated with dapsone 1.
The FDA drug label for dapsone explicitly warns that "toxic hepatitis and cholestatic jaundice have been reported early in therapy" and recommends baseline and subsequent liver function monitoring when feasible 2. If liver function abnormalities occur, dapsone should be discontinued until the source is established.
Severe Hepatotoxicity: Dapsone Hypersensitivity Syndrome
The most serious hepatic complication is dapsone hypersensitivity syndrome (DHS), also called "sulfone syndrome." This rare but potentially fatal reaction is characterized by:
- Fever
- Exfoliative dermatitis
- Hepatic dysfunction (can progress to fulminant hepatic necrosis)
- Methemoglobinemia
- Typically begins 1-4 weeks into therapy 1
DHS can cause fulminant hepatitis requiring emergency liver transplantation 3. Recent case reports document acute necrotic hepatitis with multi-organ failure necessitating urgent living donor liver transplantation in a 12-year-old girl 3. The syndrome presents with prominent hepatopulmonary manifestations and must be promptly identified as it can be fatal if untreated 4.
Mechanism of Hepatotoxicity
The cholestatic injury is caused by dapsone and its N-hydroxylated metabolites, which:
- Hinder bile flow
- Cause oxidative stress and hepatic necrosis
- Lead to hemolysis responsible for hepatitis due to iron overload in the liver 5
Clinical Monitoring Recommendations
When prescribing dapsone:
- Perform baseline liver function tests when feasible 2
- Monitor liver enzymes during therapy, particularly in the first 4-12 weeks
- Be vigilant for early signs of hypersensitivity syndrome (fever, rash, systemic symptoms)
- G6PD-deficient patients may experience hyperbilirubinemia more frequently 2
Discontinue dapsone immediately if:
- Significant liver enzyme elevations occur
- Signs of hypersensitivity syndrome develop (fever, rash, systemic symptoms)
- Clinical hepatitis is suspected
Important Caveats
Drug Interactions Affecting Hepatotoxicity
Cotrimoxazole (TMP-SMX) combined with dapsone may increase the risk of dapsone toxicity, including potential hepatic effects 6. The combination raises dapsone levels approximately 1.5-fold 2.
Context Matters
While hepatotoxicity is documented, hematologic toxicity (hemolysis, methemoglobinemia) remains the most common adverse effect of dapsone, occurring in nearly all patients to some degree 1, 2. The overall toxicity incidence in HIV-infected patients is approximately 10-13%, consisting principally of reversible hematologic effects 1.
Comparative Risk
In studies comparing immunosuppressants, mycophenolate mofetil was associated with less hepatotoxicity than azathioprine 7, though this comparison doesn't directly involve dapsone. Tetracycline, another acne treatment option, also lists hepatotoxicity and liver failure as potential adverse effects 8.
Bottom line: Clinicians must maintain awareness of dapsone's hepatotoxic potential, monitor liver function when feasible, and maintain a high index of suspicion for hypersensitivity syndrome, particularly in the first 1-4 weeks of therapy 1, 2, 5, 4.